Identification of Prognostic Factors and Role of Radiotherapy in Patients With Ewing Sarcoma

assess whether there is a correlation between some factors (age, sex, tumor volume, tumor site, chemotherapy-induced necrosis, radiation and biomarkers) and overall survival (OS) and relapse-free survival (RFS) in patients with Ewing sarcoma.

Identification of reliable prognostic factors could help to identify high-risk patients, which may require a different treatment and follow up.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Ewing Sarcoma Neoplasms Neoplasms by Histologic Type Neoplasms, Bone Tissue Neoplasms, Connective Tissue Neoplasms, Connective and Soft Tissue Osteosarcoma Sarcoma Sarcoma, Ewing

Age range

2 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

IRCCS Itituto Ortopedico Rizzoli

Bologna, BO, 40136, Italy

Location status: Recruiting

Location contact

Costantino Errani, MD

CONTACT

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male and female patients treated at Rizzoli Orthopaedic Institute between 01/01/1991 and 31/12/2021
Age ≥ 2 years
Diagnosis of Ewing Sarcoma
Patients with available clinical and imaging data

Exclusion criteria

At least one inclusion criterion not met

Treatment and study plan

clinical records review

Other

review the medical records, radiological imaging, and histological data of these patients

Primary outcomes

Correlation

Time frame: At baseline (Day 0)

Correlation between some factors (age, sex, tumor volume, tumor site, chemotherapy-induced necrosis, radiation and biomarkers) and overall survival (OS) and relapse-free survival (RFS) in patients with Ewing sarcoma.

Study contacts

Contact information is provided by the study sponsor or research team.

Costantino Errani

CONTACT

[email protected]

0516366 ext. 103

Sponsors and collaborators

Lead sponsor

Istituto Ortopedico Rizzoli

Other

Registry information

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Feb 6, 2024
Registry last updated: Mar 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting